Adding l-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial
Notes for this study:
|Values||(mm). Placebo: 6.08 (0.59). Carnitine: 10.66 (0.68)|
|Trial Design||Randomized trial|
|Trial Length||1-6 months|
|Number of Subjects||170|
|Body Types||Obese, Overweight|
This randomized controlled trial sought to investigate the effectiveness of l-carnitine on the primacy outcome of ovulation and clinical pregnancy occurrence in females with clomiphene-resistant polycystic ovary syndrome (PCOS).
Group A (n = 85) received clomiphene citrate (250 mg/day), a drug used to induce ovulation, from day 3 until day 7 of the ovulation cycle plus l-carnitine (3g/day) from day three until the day of the first positive pregnancy test.
Group B (n = 85) received 250 mg clomiphene citrate and a placebo.
The primary outcome was the cumulative clinical pregnancy rate, and the carnitine group saw a statistically significantly greater increase. Ovulation rate, endometrial thickness, the mean number of preovulatory follicles, progesterone, and estradiol were statistically significantly greater as well.
Lipid profile, glucose, and HbA1c also improved over the 12 weeks compared with pre-treatment though the researchers didn't share control group numbers and pregnancy or other factors could have confounded the findings, and they will be omitted from addition to the HEM.